Fredag 19 Juni | 17:15:23 Europe / Stockholm

Bifogade filer

Kalender

Est. tid*
2027-02-19 08:00 Bokslutskommuniké 2026
2026-10-06 08:30 Kvartalsrapport 2026-Q3
2026-08-14 08:30 Kvartalsrapport 2026-Q2
2026-05-08 - X-dag ordinarie utdelning VSD B 0.00 SEK
2026-04-10 - Kvartalsrapport 2026-Q1
2026-03-20 - Årsstämma
2026-02-13 - Bokslutskommuniké 2025
2025-11-07 - X-dag ordinarie utdelning VSD B 0.00 SEK
2025-05-15 - Extra Bolagsstämma 2025
2025-05-09 - Kvartalsrapport 2025-Q3
2025-02-07 - Kvartalsrapport 2025-Q2
2024-11-04 - X-dag ordinarie utdelning VSD B 0.00 SEK
2024-11-01 - Årsstämma
2024-10-28 - Kvartalsrapport 2025-Q1
2024-08-30 - Bokslutskommuniké 2024
2024-04-19 - Kvartalsrapport 2024-Q3
2024-04-12 - Extra Bolagsstämma 2024
2024-02-09 - Kvartalsrapport 2024-Q2
2023-10-27 - Kvartalsrapport 2024-Q1
2023-09-25 - X-dag ordinarie utdelning VSD B 0.00 SEK
2023-09-22 - Årsstämma
2023-08-31 - Bokslutskommuniké 2023
2023-05-04 - Kvartalsrapport 2023-Q3
2023-02-09 - Kvartalsrapport 2023-Q2
2022-10-27 - Kvartalsrapport 2023-Q1
2022-10-07 - X-dag ordinarie utdelning VSD B 0.00 SEK
2022-10-06 - Årsstämma
2022-08-30 - Bokslutskommuniké 2022
2022-07-05 - Extra Bolagsstämma 2022
2022-05-04 - Kvartalsrapport 2022-Q3
2022-02-11 - Kvartalsrapport 2022-Q2
2021-10-22 - Kvartalsrapport 2022-Q1
2021-10-06 - X-dag ordinarie utdelning VSD B 0.00 SEK
2021-10-05 - Årsstämma
2021-08-30 - Bokslutskommuniké 2021
2021-05-12 - Kvartalsrapport 2021-Q3
2021-02-12 - Kvartalsrapport 2021-Q2
2020-11-12 - Kvartalsrapport 2021-Q1
2020-10-08 - X-dag ordinarie utdelning VSD B 0.00 SEK
2020-10-07 - Årsstämma
2020-08-31 - Bokslutskommuniké 2020
2020-05-15 - Kvartalsrapport 2020-Q3
2020-05-04 - Extra Bolagsstämma 2020
2020-02-14 - Kvartalsrapport 2020-Q2
2019-11-01 - Kvartalsrapport 2020-Q1
2019-10-10 - X-dag ordinarie utdelning VSD B 0.00 SEK
2019-10-09 - Årsstämma
2019-08-30 - Bokslutskommuniké 2019
2019-05-16 - Kvartalsrapport 2019-Q3
2019-02-14 - Kvartalsrapport 2019-Q2
2018-10-30 - Kvartalsrapport 2019-Q1
2018-10-17 - X-dag ordinarie utdelning VSD B 0.00 SEK
2018-10-16 - Årsstämma
2018-08-31 - Bokslutskommuniké 2018
2018-05-16 - Kvartalsrapport 2018-Q3
2018-02-14 - Kvartalsrapport 2018-Q2
2017-10-30 - Kvartalsrapport 2018-Q1
2017-10-02 - X-dag ordinarie utdelning VSD B 0.00 SEK
2017-09-29 - Årsstämma
2017-08-30 - Bokslutskommuniké 2017
2017-05-22 - Kvartalsrapport 2017-Q3
2017-02-20 - Kvartalsrapport 2017-Q2
2017-01-25 - Extra Bolagsstämma 2017
2016-11-07 - Kvartalsrapport 2017-Q1
2016-08-29 - X-dag ordinarie utdelning VSD B 0.00 SEK
2016-08-26 - Bokslutskommuniké 2016
2016-05-26 - Kvartalsrapport 2016-Q3
2016-02-25 - Kvartalsrapport 2016-Q2
2015-11-26 - Kvartalsrapport 2016-Q1
2015-08-27 - Bokslutskommuniké 2015

Beskrivning

LandSverige
ListaSpotlight
SektorHälsovård
IndustriMedicinteknik
Vibrosense Dynamics är verksamt inom medicinteknik. Bolaget utvecklar produkter och tjänster för diagnostikstöd vid nervskador. Produkterna mäter förmågan att känna vibrationer i huden, och används av vårdgivare för att kunna anpassa behandlingen eller sätta in förebyggande åtgärder vid potentiella nervskador. Bolagets kunder består huvudsakligen av diabetesmottagningar, sjukhus, vårdcentraler och forskningsinstitut. Vibrosense Dynamics grundades 2005 och har sitt huvudkontor i Malmö.

Intresserad av bolagets nyckeltal?

Analysera bolaget i Börsdata!

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

2026-06-09 13:31:13

New research published in the Journal of the Peripheral Nervous System (Sloan et al., 2026) shows that the understanding of peripheral nerve damage caused by diabetes (DPN) is shifting. DPN has long been regarded as irreversible, but a growing number of studies suggest that nerve damage can be reversed, especially if the condition is detected early.

The current publication provides a review of research both supporting and opposing the possibility of reversing diabetes-related nerve damage. The researchers' key message in favour of reversibility is that it depends on timing. Early nerve dysfunction is functional and potentially modifiable. Once structural damage has been established, the possibilities are limited. Lifestyle changes and new treatment approaches have in several studies produced measurable improvements in nerve function.
This represents a shift in consensus that opens up new opportunities, both for patients and for the clinicians working in diabetes care. The researchers explicitly highlight the need for standardised measurement methods for early nerve dysfunction as a priority for future research and clinical practice.
The arguments against the reversibility of nerve damage are largely based on the fact that the damage is caused by impaired microcirculation. Since it has not been clinically demonstrated that such a condition can be improved, this serves as an indirect argument against the reversibility of nerve damage. Another argument against is that it is difficult to measure nerve function using available methods.

 "This is a very interesting publication where both the arguments for and against support our instrument VibroSense Meter II as an objective and reliable tool for assessing nerve function. Other existing methods are far too coarse, which in turn means that small changes cannot be detected", says Toni Speidel, CEO of VibroSense Dynamics AB.

Read the full article at  Sloan G et al. Journal of the Peripheral Nervous System, 2026; 31:e70124. doi: 10.1111/jns.70124

For more information, please contact:
Toni Speidel, CEO
VibroSense Dynamics AB (publ) 
Tel: +46 40 88 026
E-mail: info@vibrosense.se
www.vibrosense.se
"The new Gold Standard for reliable
detection of nerve damage"

About VibroSense Dynamics AB (publ)
VibroSense Dynamics AB (publ) develops and sells medical device products and services for diagnostic support in the assessment of nerve damage in hands and feet. The method involves measuring and quantifying the ability to perceive vibrations at multiple frequencies applied to the skin. The company's customers include diabetes clinics, occupational health services, hospitals, primary care centres, and researchers.
Our vision is for the company's products to become a standard instrument in all neurological examinations, in order to detect early signs of changes in sensation so that patients and their healthcare providers can implement preventive measures that prevent, reduce, or delay the onset of nerve damage in the hands and feet.